Uscom (ASX:UCM) has announced the publication of a new independent study that it says demonstrates the equivalence of catheter based measures of central blood pressure with non-invasive Uscom measurements.
The study was published in Critical Care Medicine and will be presented at the Annual Scientific Meeting of the Society of Critical Care Medicine (SCCM) in Orlando, February 20-24th, 2016.
According to the company, the study from the Great Ormond Street Hospital for Children (GOSH) demonstrates the equivalence of catheter based measures of central blood pressure (cBP) with non-invasive Uscom BP+ cBP measurements.
The study found that, in 1 to 18 year old children, there was no significant difference in measures of cBP directly from aortic catheters and those from the Uscom BP+.
The GOSH study states: “we will be able to target arterial BP non-invasively for monitoring and treatment and we believe this is going to change practice.”
The study also states that following these promising findings GOSH will undertake further research on the Uscom BP+ and its application in advanced haemodynamics and cBP monitoring.
The Uscom BP+ uses patent protected supra systolic oscillometry to measure cBP non-invasively, and has previously been invasively validated in adults. The BP+ is currently on board the International Space Station for critical monitoring of brachial BP and cBP in astronauts.
This validation in children and adolescents further expands the potential clinical utility and market for the Uscom BP+, and comes at a time when the CPT Code for reimbursement of measurement of cBP comes into effect in the US.
Executive Chairman of Uscom, Associate Professor Rob Phillips, said: “This invasive validation of cBP in children and adolescents is unique, and represents a significant step forward for the science of BP monitoring, confirming that BP+ can be used as a 'noninvasive art line' in adults and now children. cBP is an emerging and competitive field, but most devices use simple generalised transfer functions of variable accuracy, estimated from cuff-based, sub systolic oscillometric measurements and are not validated in children. The Uscom BP+ uses patent protected supra systolic oscillometry which has theoretical physiologic advantages to other methods and which are now being recognised in clinical research. This independent endorsement of Uscom cBP technology is further evidence of the excellence, precision and leadership of Uscom science and confirms the commercial opportunity of our BP+ as we finalise its preparation for market.”